IBEX Ltd IBEX 深 滬
等待開盤 07-24 09:30:00 美东时间
32.21
-0.890
-2.69%
華盛通- 最 高33.065
- 今 開32.86
- 成交量 8.91万股
- 最 低 32.105
- 昨 收 33.10
- 總市值 4.31亿
- 52周最高 42.99
- 市盈率 靜 13.67
- 換手率 0.67%
- 52周最低 25.94
- 委 比 -26.58%
- 總股本 1338.91万
- 歷史最高 42.99
- 量 比 0.89
- 振 幅 2.90%
- 歷史最低 9.27
- 每 手 1
- 風險率 4.21%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Grifols Doses First Patients in Two Phase 3 Trials to Expand Indications of its Flagship Immunoglobulins
Grifols has initiated two Phase 3 trials to expand U.S. labels for its immunoglobulin therapies, GAMUNEX-C and XEMBIFY. The SIGMA trial evaluates GAMUNEX-C in preventing infections in patients with secondary immunodeficiency, particularly those with blood cancers. The XPERT trial compares XEMBIFY's efficacy and safety to GAMUNEX-C in treating Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP). Both studies aim to provide more treatm...
07-16 12:00
全球科技上半年迎牛市狂欢 最大赢家却不在美国
科技行业在2026年上半年成为全球股市的明显赢家。尽管6月末遭遇一轮猛烈抛售，美国大型科技股录得可观涨幅，然而其表现仍整体落后于海外同业。
07-02 11:15
ibex Honors the Winners of the 5th Annual CX Leadership Awards at CCW Las Vegas
LAS VEGAS, July 01, 2026 (GLOBE NEWSWIRE) -- ibex, a global leader in outsourced business services and AI-powered customer experience solutions, announced the winners of the 2026 CX Leadership Awards. These awards recognize top CX innovators and leaders worldwide. This year’s winners, selected from a strong list of professionals, were honored at ibex’s Fifth Annual CX Leadership Awards Dinner during Customer Contact Week (CCW) in Las Vegas. Winne...
07-01 13:00
ibex Names Shannon Hodges Senior Vice President of Wave iX
ibex appoints Shannon Hodges as Senior Vice President of Wave iX, its AI-powered customer experience solutions suite. Hodges, with over 25 years of experience in customer growth and operations, will lead the expansion of Wave iX, driving AI adoption and optimizing customer experiences for clients. His expertise will help ibex deliver seamless, end-to-end customer journeys by combining AI technology with human expertise.
06-17 13:00
Grifols Launches FESILTY™ (fibrinogen, human-chmt) in the U.S.
Grifols has launched FESILTY, a new fibrinogen concentrate in the U.S. for treating acute bleeding in pediatric and adult patients with congenital fibrinogen deficiency. FESILTY offers a rapid, predictable, and reliable treatment option, enhancing Grifols' bleeding management portfolio. It is a purified product that can be stored at room temperature and reconstituted quickly. Clinical studies have confirmed its efficacy and safety, providing a va...
06-15 12:00
